Advanced search×

A systematic review of occupational safety and health business cases.

Jos Verbeek, Marjo Pulliainen, and Eila Kankaanpää

Scand J Work Environ Health 35(6):403-12 (2009) PMID 19806275

Business cases are commonly developed as means to rationalize investment. We systematically reviewed 26 reported cases on occupational safety and health (OSH) interventions to assess if health and productivity arguments make a good business case.

Version: za2963e q8za2 q8zbb q8zca q8zda q8zeb q8zfb q8zga
Buy PDF

Similar articles you may find interesting…

  1. Trends in the medical management of patients with heart failure.
    Samuel W Joffe, Matthew Dewolf, and Robert J Goldberg

    J Clin Med Res 5(3):194-204 (2013) PMID 23671545

    We reviewed the medical records of 9,748 residents of the Worcester, MA, metropolitan area who were hospitalized with ADHF at all 11 central Massachusetts medical centers in 1995, 2000, 2002, and 2004. Between 1995 and 2004, respectively, the prescription upon hospital discharge of b...
    PDF not found
  2. Peptide-binding motifs and characteristics for HLA -B*13:01 molecule.
    J Zhang, H Yang, and Y Dai

    Tissue Antigens 81(6):442-8 (2013) PMID 23646949

    We searched for peptides bound to the HLA-B*13:01 molecule; 57 HLA-B*13:01-bound peptides in total were identified and 54 peptides were used to calculate frequency of amino acid residues to obtain binding motifs of HLA-B*13:01 molecule. The results showed P2, P3, and P9 were the primary binding anch...
    Buy PDF
  3. Imidafenacin for the treatment of overactive bladder.
    Umberto Leone Roberti Maggiore, Carolina Scala, and Simone Ferrero

    Expert Opin Pharmacother (2013) PMID 23641864

    Imidafenacin (KRP-197/ONO-8025) is the latest antimuscarinic (AM) developed for the treatment of overactive bladder syndrome (OAB) and, at the moment, it is marketed only in Japan. This compound has been developed to improve the tolerability of AM therapy by binding specifically the M3 receptor subt...
    Buy PDF